NASDAQ:PRTG Portage Biotech (PRTG) Stock Price, News & Analysis $0.15 0.00 (-2.05%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$0.14▼$0.1550-Day Range$0.15▼$0.4852-Week Range$0.13▼$3.95Volume511,934 shsAverage Volume342,235 shsMarket Capitalization$2.63 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Portage Biotech alerts: Email Address Portage Biotech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside5,529.1% Upside$8.50 Price TargetShort InterestHealthy0.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 stars 3.3 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePortage Biotech has received no research coverage in the past 90 days.Read more about Portage Biotech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.63% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 0.6 News and Social Media Coverage Search Interest3 people have searched for PRTG on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 13.36% of the stock of Portage Biotech is held by institutions.Read more about Portage Biotech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Portage Biotech are expected to grow in the coming year, from ($1.03) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Portage Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent] Hedge Funds Expect Major Crypto MovesIn the year following Bitcoin’s last Halving event, that happened in May of 2020… Bitcoin shot up over 550%. But that’s not all… Click here to register now. About Portage Biotech Stock (NASDAQ:PRTG)Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Read More PRTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTG Stock News HeadlinesJune 29, 2024 | americanbankingnews.comReviewing Comstock Resources (NYSE:CRK) & Portage Biotech (NASDAQ:PRTG)May 16, 2024 | uk.investing.comPortage Biotech Inc (PRTG)July 8, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.April 14, 2024 | investing.comPortage Biotech halts trial enrollment, seeks strategic optionsApril 12, 2024 | msn.comPortage Down on Announcing AlternativesApril 12, 2024 | globenewswire.comPortage Biotech Announces Plans to Expand its Evaluation of Strategic AlternativesMarch 26, 2024 | globenewswire.comPortage Biotech Completes Monetization of Intensity Therapeutics (INTS) sharesMarch 11, 2024 | finance.yahoo.comPRTG: Extending the RunwayJuly 8, 2024 | Chaikin Analytics (Ad)50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the start of the year.March 3, 2024 | morningstar.comPortage Biotech Inc PRTGFebruary 28, 2024 | globenewswire.comPortage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business UpdateJanuary 8, 2024 | realmoney.thestreet.comH.C. Wainwright downgrades Portage Biotech on financing overhangJanuary 8, 2024 | realmoney.thestreet.comPortage Biotech just downgraded at H.C. Wainwright, here's whyJanuary 8, 2024 | finance.yahoo.comPRTG: Bridging I-O: Working in Harmony with CheckpointsJanuary 4, 2024 | marketwatch.comPortage Biotech Shares Fall 6% on Job Reductions, Paused Drug Development ProgramJanuary 4, 2024 | markets.businessinsider.comPortage Biotech To Pause INKT Clinical Development; To Evaluate Potential Strategic OptionsJanuary 4, 2024 | msn.comPortage Biotech to halt iNKT drug program, cut workforceJanuary 4, 2024 | finance.yahoo.comPortage Biotech Reports Business and Strategic UpdateSee More Headlines Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2023Today7/08/2024Next Earnings (Estimated)9/04/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Crude petroleum & natural gas Sub-IndustryN/A Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+5,529.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-177.66% Return on Assets-129.14% Debt Debt-to-Equity Ratio0.01 Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.45 per share Price / Book0.03Miscellaneous Outstanding Shares17,800,000Free FloatN/AMarket Cap$2.69 million OptionableOptionable Beta1.47 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Ian B. Walters M.B.A. (Age 56)M.D., CEO & Chairman of Board Comp: $967.65kMr. Allan J. Lee Shaw CPA (Age 60)Chief Financial Officer Comp: $524.08kDr. Robert A. Kramer Ph.D.Chief Scientific OfficerMr. Brian Wiley (Age 56)Chief Business Officer Comp: $220.69kMr. Justin FairchildVice President of DevelopmentMr. Joseph CiavarellaChief Accounting OfficerMore ExecutivesKey CompetitorsEcopetrolNYSE:ECNew Concept EnergyNYSE:GBRVOC Energy TrustNYSE:VOCWoodside Energy GroupNYSE:WDSShellNYSE:SHELView All Competitors PRTG Stock Analysis - Frequently Asked Questions How have PRTG shares performed this year? Portage Biotech's stock was trading at $1.82 at the beginning of 2024. Since then, PRTG stock has decreased by 91.7% and is now trading at $0.1510. View the best growth stocks for 2024 here. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) issued its quarterly earnings results on Wednesday, November, 29th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.02. How do I buy shares of Portage Biotech? Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTG) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.